336 related articles for article (PubMed ID: 33472824)
1. Limbic Neuropeptidergic Modulators of Emotion and Their Therapeutic Potential for Anxiety and Post-Traumatic Stress Disorder.
Marvar PJ; Andero R; Hurlemann R; Lago TR; Zelikowsky M; Dabrowska J
J Neurosci; 2021 Feb; 41(5):901-910. PubMed ID: 33472824
[TBL] [Abstract][Full Text] [Related]
2. Administration of moclobemide facilitates fear extinction and attenuates anxiety-like behaviors by regulating synaptic-associated proteins in a rat model of post-traumatic stress disorder.
Xiao B; Han F; Shi Y
Synapse; 2020 Jun; 74(6):e22146. PubMed ID: 31869485
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.
Singewald N; Schmuckermair C; Whittle N; Holmes A; Ressler KJ
Pharmacol Ther; 2015 May; 149():150-90. PubMed ID: 25550231
[TBL] [Abstract][Full Text] [Related]
4. The Melatonergic System in Anxiety Disorders and the Role of Melatonin in Conditional Fear.
Huang F; Yang Z; Li CQ
Vitam Horm; 2017; 103():281-294. PubMed ID: 28061973
[TBL] [Abstract][Full Text] [Related]
5. Regulation of fear extinction versus other affective behaviors by discrete cortical scaffolding complexes associated with NR2B and PKA signaling.
Corcoran KA; Leaderbrand K; Jovasevic V; Guedea AL; Kassam F; Radulovic J
Transl Psychiatry; 2015 Oct; 5(10):e657. PubMed ID: 26460481
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin type 1 receptor inhibition enhances the extinction of fear memory.
Marvar PJ; Goodman J; Fuchs S; Choi DC; Banerjee S; Ressler KJ
Biol Psychiatry; 2014 Jun; 75(11):864-72. PubMed ID: 24094510
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone facilitates fear extinction and safety discrimination in PTSD: A placebo-controlled, double-blind study.
Michopoulos V; Norrholm SD; Stevens JS; Glover EM; Rothbaum BO; Gillespie CF; Schwartz AC; Ressler KJ; Jovanovic T
Psychoneuroendocrinology; 2017 Sep; 83():65-71. PubMed ID: 28595089
[TBL] [Abstract][Full Text] [Related]
8. Effects of intranasal oxytocin on distraction as emotion regulation strategy in patients with post-traumatic stress disorder.
Koch SBJ; van Zuiden M; Nawijn L; Frijling JL; Veltman DJ; Olff M
Eur Neuropsychopharmacol; 2019 Dec; 29(2):266-277. PubMed ID: 30554861
[TBL] [Abstract][Full Text] [Related]
9. Acute and long-lasting effects of oxytocin in cortico-limbic circuits: consequences for fear recall and extinction.
Triana-Del Río R; van den Burg E; Stoop R; Hegoburu C
Psychopharmacology (Berl); 2019 Jan; 236(1):339-354. PubMed ID: 30302511
[TBL] [Abstract][Full Text] [Related]
10. Investigating the role of the amygdala orexin receptor 1 in memory acquisition and extinction in a rat model of PTSD.
Salehabadi S; Abrari K; Elahdadi Salmani M; Nasiri M; Lashkarbolouki T
Behav Brain Res; 2020 Apr; 384():112455. PubMed ID: 32044404
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid modulating drugs improve anxiety but not the expression of conditioned fear in a rodent model of post-traumatic stress disorder.
Vimalanathan A; Gidyk DC; Diwan M; Gouveia FV; Lipsman N; Giacobbe P; Nobrega JN; Hamani C
Neuropharmacology; 2020 Apr; 166():107965. PubMed ID: 31962287
[TBL] [Abstract][Full Text] [Related]
12. Reconsolidation/destabilization, extinction and forgetting of fear memory as therapeutic targets for PTSD.
Kida S
Psychopharmacology (Berl); 2019 Jan; 236(1):49-57. PubMed ID: 30374892
[TBL] [Abstract][Full Text] [Related]
13. The endocannabinoid system in the amygdala and modulation of fear.
Gunduz-Cinar O
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110116. PubMed ID: 32976951
[TBL] [Abstract][Full Text] [Related]
14. Differential roles of the infralimbic and prelimbic areas of the prefrontal cortex in reconsolidation of a traumatic memory.
Levin N; Kritman M; Maroun M; Akirav I
Eur Neuropsychopharmacol; 2017 Sep; 27(9):900-912. PubMed ID: 28647452
[TBL] [Abstract][Full Text] [Related]
15. From recent advances in underlying neurocircuitry of fear and anxiety to promising pharmacotherapies for PTSD: The saga of heart, sex and the developing brain.
Dabrowska J
Neuropharmacology; 2023 Jul; 232():109529. PubMed ID: 37004751
[TBL] [Abstract][Full Text] [Related]
16. Animal models of post-traumatic stress disorder and novel treatment targets.
Aspesi D; Pinna G
Behav Pharmacol; 2019 Apr; 30(2 and 3-Spec Issue):130-150. PubMed ID: 30741728
[TBL] [Abstract][Full Text] [Related]
17. Rodent models of impaired fear extinction.
Singewald N; Holmes A
Psychopharmacology (Berl); 2019 Jan; 236(1):21-32. PubMed ID: 30377749
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological rewriting of fear memories: A beacon for post-traumatic stress disorder.
Uniyal A; Singh R; Akhtar A; Dhaliwal J; Kuhad A; Sah SP
Eur J Pharmacol; 2020 Mar; 870():172824. PubMed ID: 31778672
[TBL] [Abstract][Full Text] [Related]
19. Role of dopamine D3 receptor in alleviating behavioural deficits in animal models of post-traumatic stress disorder.
Song D; Ge Y; Chen Z; Shang C; Guo Y; Zhao T; Li Y; Wu N; Song R; Li J
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):190-200. PubMed ID: 29510167
[TBL] [Abstract][Full Text] [Related]
20. Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research.
Papini S; Sullivan GM; Hien DA; Shvil E; Neria Y
Biol Psychol; 2015 Jan; 104():8-18. PubMed ID: 25448242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
